Back to Cancer Australia's website

Cancer Australia

Select a guideline

Recommendations for use of Trastuzumab (Herceptin®)

Ongoing and additional trials or studies

A number of ongoing phase III trials are investigating the use of trastuzumab in HER2-positive breast cancer:

  • five ongoing trials investigating the use of trastuzumab in early breast cancer (BIG-01-01 (HERA);38 NSABP-B31;39NCCTG-N9831;19 UCLA-0102006 (BCIRG 006);40FRE-FNCLCC-PACS-04/000541)
  • three ongoing trials investigating the use of trastuzumab as preoperative therapy (CLB 49808;42 GBG-GEPARQUATTRO;43ID99-14644)
  • four ongoing trials investigating the use of trastuzumab in metastatic breast cancer (SWS-SAKK-22/99;45 EGF 104383;46 UCLA-0109024 (BCIRG-007)47)
  • three ongoing trials investigating the continued use of trastuzumab post-progression (SWOG SO347;48 GBG26;49 EGF 10490050).

Published using CeCC Docbook Manager